Current and Emerging Pharmacologic Therapies for Diabetic Retinopathy. [PDF]
PharmacotherapyABSTRACT Diabetic retinopathy, a prevalent microvascular complication of diabetes mellitus, is a leading cause of blindness among adults in developed countries. Risk factors include prolonged duration of diabetes, elevated glycosylated hemoglobin levels, hypertension, and dyslipidemia, with rapid glucose reduction also increasing risk for developing ...
Clements JN, Mesawich J, Twisdale C.
europepmc +2 more sources
PLoS ONE, 2020 PurposeTo evaluate the effectiveness, safety, and treatment patterns of ranibizumab 0.5 mg in prior ranibizumab-treated patients with neovascular age-related macular degeneration (nAMD) enrolled in the LUMINOUS™ study.Patients and methodsLUMINOUS, a 5 ...
Frank G Holz +6 more
doaj +1 more source
Treatment as required versus regular monthly treatment in the management of neovascular age-related macular degeneration: a systematic review and meta-analysis [PDF]
, 2015 Background: To investigate whether treatment as required ‘pro re nata’ (PRN) versus regular monthly treatment regimens lead to differences in outcomes in neovascular age-related macular degeneration (nAMD).
Agostini, Hansjuergen +7 more
core +3 more sources
Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson's Disease: A Case Report. [PDF]
, 2018 In November 2012, a 72-year old patient was diagnosed with left eye wet age-related macular degeneration. The patient received three monthly intravitreal injections of ranibizumab, with complete resolution of retinal hemorrhage and edema and ...
Antonini +43 more
core +2 more sources
Intravitreal injection of Ozurdex(®) implant in patients with persistent diabetic macular edema, with six-month follow-up [PDF]
, 2016 AIM: To evaluate the efficacy of intravitreal dexamethasone injections in diabetic macular edema (DME). METHODS: A 700 μg slow-release intravitreal dexamethasone implant (Ozurdex®) was placed in the vitreal cavity of 17 patients (19 eyes) affected ...
Bottone, A +8 more
core +6 more sources
Cost effectiveness of treatments for wet age-related macular degeneration [PDF]
, 2011 Age-related macular degeneration (AMD) is a leading cause of blindness in people aged >= 50 years. Wet AMD in particular has a major impact on patient quality of life and imposes substantial burdens on healthcare systems.
Annemans, Lieven +4 more
core +1 more source
Protective effects on the retina after ranibizumab treatment in an ischemia model. [PDF]
PLoS ONE, 2017 Retinal ischemia is common in eye disorders, like diabetic retinopathy or retinal vascular occlusion. The goal of this study was to evaluate the potential protective effects of an intravitreally injected vascular endothelial growth factor (VEGF ...
Stephanie C Joachim +10 more
doaj +1 more source
Widening use of dexamethasone implant for the treatment of macular edema [PDF]
, 2017 Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious uveitis.
Avitabile T. +9 more
core +2 more sources
Clinical Ophthalmology, 2021 Faye Horner, Peck Lin Lip, Bashar R Mohammed, William Fusi-Rubiano, Eesha Gokhale, Bushra Mushtaq, Randhir Chavan Birmingham & Midland Eye Centre, Birmingham, UKCorrespondence: Randhir ChavanBirmingham & Midland Eye Centre, Sandwell & West ...
Horner F +6 more
doaj
Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment : evidence from the RESTORE trial [PDF]
, 2012 Background/aims To evaluate the cost-effectiveness of ranibizumab as either monotherapy or combined with laser therapy, compared with laser monotherapy, in the treatment of diabetic macular oedema (DME) causing visual impairment from a UK healthcare ...
Mitchell, Paul +7 more
core +2 more sources